P03-131

NITHSDALE SCHIZOPHRENIA SURVEY: USE OF ANTIPSYCHOTIC MEDICATIONS IN A SCHIZOPHRENIA POPULATION

S. Shivashankar¹, S. Telfer², J. Arunagiriraj³, M. McKinnon⁴, R. McCreadie⁵

¹Suffolk Mental Health Partnership NHS Trust, Bury St Edmunds, ²Greater Glasgow & Clyde NHS Trust, Glasgow, ³Dumfries & Galloway Primary Care Trust, Dumfries, UK, ⁴Waikato Hospital, Waikato, New Zealand, ⁵Dumfries & Galloway NHS Board, Dumfries, UK

Aims: Antipsychotics are mainstay treatment in schizophrenia; atypicals including clozapine were widely used. Clozapine was considered different due to its distinct effectiveness. We report the clinical profile of these groups.

Method: In Nithsdale, South-west Scotland, the schizophrenia population was identified by 'key informant' method in 2006. The clinical variables were determined and compared between the groups.

Results: The study identified 205 people with schizophrenia (point prevalence: 3.7/1000 general population) of which 131(64%) took part in the study. 22(17%) were receiving typicals, 63(48%) atypicals excluding clozapine, 29(22%) clozapine, 8(6%) combination of typical and atypicals, and 9(7%) were on no antipsychotic medications.

Comparison between atypicals excluding clozapine, typicals and clozapine groups showed: clozapine group were younger than atypicals and typicals (Mean years: 43,54 and 62, p=< 0.001). The length of illness was longer in typicals than atypicals and clozapine (Mean years: 35,24 and 18,p=0.002).

With mental state, clozapine group had higher score in positive subscore of PANSS than that of atypicals and typicals (Mean: 1.83,1.52 and 1.21, p=< 0.001); while there were no significant differences in the negative subscore (Mean: 2.11,2.01 and 1.77, p=0.24).

Tardive dyskinesia was more prevalent in typicals and clozapine groups than atypicals as assessed by AIMS scale (Mean: 41,41 and 18, p=0.02); while there were no significant differences between the three groups in the severity of parkinsonism as assessed by Simpson & Angus scale (Mean: 0.34,0.36 and 0.25, p=0.37).

Conclusions: Atypicals including clozapine were no better than typicals in symptom control or in the neurological side effect profile.